# Biotech
Latest news and articles about Biotech
Total: 8 articles found
Beijing’s New Blueprint: China Launches High-Stakes Action Plan to Halt Foreign Capital Flight
China has released a comprehensive inter-agency roadmap to stabilize and optimize foreign investment, focusing on expanding market access in finance, healthcare, and services. The plan aims to address long-standing corporate grievances regarding data security laws, M&A hurdles, and unequal treatment in government procurement.
The AI Pipeline Factory: China’s HBM and BioMap Forge a New Frontier in Tech-Bio
HBM Holdings and BioMap have launched MegaStream TechBio, a joint venture dedicated to designing complex macromolecules using generative AI foundation models. The initiative seeks to transition the industry from traditional trial-and-error methods to a predictive 'AI Pipeline Factory' model that integrates high-throughput physical validation with computational design.
ByteDance’s Biological Breakout: Why the TikTok Maker is Spinning Off Its AI Drug Lab
ByteDance is spinning off its AI drug discovery unit into an independent entity to bridge the gap between high-speed internet culture and the slow-burn reality of pharmaceutical R&D. Despite technical breakthroughs in undruggable targets, the move reflects a strategic shift toward seeking external capital to fund long-cycle biotech ventures.
The Price of Ambiguity: Why China’s Cardiovascular Giant Salubris is Crashing
Shenzhen Salubris Pharmaceuticals shares hit consecutive limit-down floors after its flagship heart failure drug failed to show statistically significant results in Phase II trials. The sell-off reflects growing investor impatience with China's biotech sector as companies struggle to transition from generics to true innovation.
Semiconductor Surge Buffers Hong Kong Markets as Biotech Falters Amid Regulatory Headwinds
Hong Kong's Hang Seng Index remained flat as a 6% rally in semiconductor giants SMIC and Hua Hong was offset by a sharp decline in the biotech sector. Positive industrial profit data from the mainland provided a floor for the market amidst ongoing regulatory shifts in the healthcare industry.
China’s Pharma Roadmap: Beijing Unveils Strategic Pivot to High-Value Innovation and AI Integration
China's MIIT has announced the framework for the 15th Five-Year Plan for the pharmaceutical industry, focusing on accelerating drug innovation, lowering prices through AI integration, and addressing the needs of elderly and rare-disease patients. The policy aims to balance industrial growth with public affordability while positioning Chinese biotech as a competitive global force.
AbbVie Taps Chinese Innovation in $745 Million Bet on Next-Generation Pain Relief
Haisco Pharmaceutical has signed a global licensing deal with AbbVie for its Nav1.8 pain inhibitor, worth up to $745 million. The agreement grants AbbVie exclusive rights outside of Greater China and highlights the shift toward Chinese-developed innovative therapies in the global market.
NVIDIA’s Strategic Gambit and Biotech M&A Surge Fuel Wall Street Rally
US markets opened strongly on March 31, 2026, driven by NVIDIA’s $2 billion investment in Marvell and a massive wave of biotech acquisitions by Biogen and Eli Lilly. This tech and healthcare-led rally stands in stark contrast to European markets, which faced a double-digit decline over the course of the month.